Qiagen (NYSE:QGEN) PT Lowered to $45.00

Qiagen (NYSE:QGEN - Free Report) had its target price lowered by Stifel Nicolaus from $55.00 to $45.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a hold rating on the stock.

QGEN has been the subject of a number of other reports. Morgan Stanley upgraded shares of Qiagen from an equal weight rating to an overweight rating and boosted their target price for the company from $49.48 to $51.00 in a report on Friday, February 16th. JPMorgan Chase & Co. boosted their price objective on shares of Qiagen from $50.00 to $52.00 and gave the stock an overweight rating in a research note on Thursday, February 8th. Finally, Citigroup decreased their target price on shares of Qiagen from $61.86 to $60.00 and set a buy rating for the company in a research note on Thursday, February 8th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of Moderate Buy and an average price target of $50.95.

Qiagen Stock Performance

Shares of QGEN stock traded up $0.48 during mid-day trading on Wednesday, hitting $42.81. The stock had a trading volume of 1,467,683 shares, compared to its average volume of 1,228,341. Qiagen has a fifty-two week low of $34.74 and a fifty-two week high of $47.70. The firm has a market cap of $9.77 billion, a PE ratio of 28.71, a PEG ratio of 3.58 and a beta of 0.41. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.99 and a quick ratio of 1.62. The company's 50-day simple moving average is $42.56 and its 200-day simple moving average is $42.71.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings results on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.44 by $0.02. The business had revenue of $459.00 million during the quarter, compared to the consensus estimate of $453.91 million. Qiagen had a net margin of 17.38% and a return on equity of 12.50%. The business's revenue was down 5.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.53 EPS. Sell-side analysts anticipate that Qiagen will post 2.09 earnings per share for the current year.

Institutional Trading of Qiagen

Institutional investors and hedge funds have recently modified their holdings of the business. Riverview Trust Co acquired a new stake in shares of Qiagen during the first quarter worth $28,000. Tower Research Capital LLC TRC grew its position in shares of Qiagen by 66.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 710 shares of the company's stock worth $31,000 after acquiring an additional 283 shares during the last quarter. Briaud Financial Planning Inc bought a new position in shares of Qiagen during the third quarter worth about $31,000. Park Place Capital Corp bought a new position in shares of Qiagen during the first quarter worth about $36,000. Finally, Quarry LP bought a new position in shares of Qiagen during the fourth quarter worth about $38,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.